Research
Overview
Latest Research
Half a Billion Euros Funding Post-Infectious Disease Research
November 13th, 2025Germany is investing heavily in research on post-infectious diseases, long COVID or ME/CFS, to better understand and treat these conditions. You may need a browser translator for this article as it is in German.
NVG-2089: Next-Generation IVIG Enters Phase 2 Trials
November 7th, 2025Rockefeller startup launches Phase 2 trials of NVG-2089, a next-generation synthetic IVIG designed to offer more powerful and potentially safer treatment options for severe autoimmune diseases, including CIDP. Early Phase 1 data showed promising efficacy with minimal side effects.
Gene Therapy Clinical Trial to Start in October for SFN Pain
September 5th, 2025A clinical trial using gene therapy to reduce severe pain from SFN is set to begin in October. If you are in the Boston area, you may be eligible to participate.
From Pain-Centric to Multi-Symptom Small Fiber Neuropathy
August 25th, 2025This study aimed to characterize the symptomatic variability of SFN and determine whether patients can be stratified into meaningful subgroups.
Low Dose Naltrexone Shows Promise for SFN
August 20th, 2025LDN may improve symptoms in cryptogenic SFN, especially sensory and autonomic domains.
Share feedback, ideas, or information corrections in our quick anonymous survey to help improve the SFN Foundation website.
Google Form Survey